 hyperprolactinemia increas hypoprolactinemia decreas hydroxylas messeng acid level arcuat nuclei substantia nigra zona incerta effect hypoprolactinemia hyperprolactinemia tyrosin hydroxylas TH signal level dopaminerg neuron rat TH signal level rel TH quantiti arcuat nuclei zona incerta substantia nigra situ hybrid immunocytochemistri catalyt activ TH stalk-median emin sme vitro rate dopa accumul dopa decarboxylas brocresin chronic administr bromocriptin bromo dopamin DA agonist day rat prl rprl level vehicle-tr control bromo treatment TH mrna signal level arcuat nuclei intens TH arcuate-median emin area rate dopa accumul sme concomit administr ovin prl oprl effect bromo TH TH mrna signal level intens TH immunostain rate dopa accumul treatment oprl day TH mrna signal level arcuat nuclei TH activ sme vehicl chronic treatment haloperidol DA antagonist circul level endogen rprl TH activ sme similar oprl treatment contrast mrna level arcuat nuclei haloperidol-tr rat similar level vehicle-tr anim effect prl TH speci specif oprl rprl jugular vein osmot minipump TH mrna level arcuat nuclei control level oprl rprl administr TH mrna level DA perikarya zona incerta substantia nigra treatment DA agonist DA antagonist prl result hypoprolactinemia hyperprolactinemia TH mrna level tuberoinfundibular dopaminerg neuron alter TH mrna content decreas TH activ hypoprolactinemia hyperprolactinemia